Targeted treatment for osteoarthritis: drugs and delivery system
The management of osteoarthritis (OA) is a clinical challenge due to the particular avascular, dense, and occluded tissue structure. Despite numerous clinical reports and animal studies, the pathogenesis and progression of OA are still not fully understood. On the basis of traditional drugs, a large...
Main Authors: | , , , , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
Taylor & Francis Group
2021-01-01
|
Series: | Drug Delivery |
Subjects: | |
Online Access: | http://dx.doi.org/10.1080/10717544.2021.1971798 |
id |
doaj-60c21982217a4db7bae28f9e8b0a987e |
---|---|
record_format |
Article |
spelling |
doaj-60c21982217a4db7bae28f9e8b0a987e2021-09-20T12:43:20ZengTaylor & Francis GroupDrug Delivery1071-75441521-04642021-01-012811861187610.1080/10717544.2021.19717981971798Targeted treatment for osteoarthritis: drugs and delivery systemLiwei Mao0Wei Wu1Miao Wang2Jianmin Guo3Hui Li4Shihua Zhang5Jiake Xu6Jun Zou7School of Kinesiology, Shanghai University of SportSchool of Kinesiology, Shanghai University of SportSchool of Kinesiology, Shanghai University of SportSchool of Kinesiology, Shanghai University of SportSchool of Kinesiology, Shanghai University of SportSchool of Kinesiology, Shanghai University of SportSchool of Biomedical Sciences, The University of Western AustraliaSchool of Kinesiology, Shanghai University of SportThe management of osteoarthritis (OA) is a clinical challenge due to the particular avascular, dense, and occluded tissue structure. Despite numerous clinical reports and animal studies, the pathogenesis and progression of OA are still not fully understood. On the basis of traditional drugs, a large number of new drugs have been continuously developed. Intra-articular (IA) administration for OA hastens the development of targeted drug delivery systems (DDS). OA drugs modification and the synthesis of bioadaptive carriers contribute to a qualitative leap in the efficacy of IA treatment. Nanoparticles (NPs) are demonstrated credible improvement of drug penetration and retention in OA. Targeted nanomaterial delivery systems show the prominent biocompatibility and drug loading-release ability. This article reviews different drugs and nanomaterial delivery systems for IA treatment of OA, in an attempt to resolve the inconsonance between in vitro and in vivo release, and explore more interactions between drugs and nanocarriers, so as to open up new horizons for the treatment of OA.http://dx.doi.org/10.1080/10717544.2021.1971798osteoarthritisintra-articular treatmentnanoparticlesdrug delivery systemtargeted treatment |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Liwei Mao Wei Wu Miao Wang Jianmin Guo Hui Li Shihua Zhang Jiake Xu Jun Zou |
spellingShingle |
Liwei Mao Wei Wu Miao Wang Jianmin Guo Hui Li Shihua Zhang Jiake Xu Jun Zou Targeted treatment for osteoarthritis: drugs and delivery system Drug Delivery osteoarthritis intra-articular treatment nanoparticles drug delivery system targeted treatment |
author_facet |
Liwei Mao Wei Wu Miao Wang Jianmin Guo Hui Li Shihua Zhang Jiake Xu Jun Zou |
author_sort |
Liwei Mao |
title |
Targeted treatment for osteoarthritis: drugs and delivery system |
title_short |
Targeted treatment for osteoarthritis: drugs and delivery system |
title_full |
Targeted treatment for osteoarthritis: drugs and delivery system |
title_fullStr |
Targeted treatment for osteoarthritis: drugs and delivery system |
title_full_unstemmed |
Targeted treatment for osteoarthritis: drugs and delivery system |
title_sort |
targeted treatment for osteoarthritis: drugs and delivery system |
publisher |
Taylor & Francis Group |
series |
Drug Delivery |
issn |
1071-7544 1521-0464 |
publishDate |
2021-01-01 |
description |
The management of osteoarthritis (OA) is a clinical challenge due to the particular avascular, dense, and occluded tissue structure. Despite numerous clinical reports and animal studies, the pathogenesis and progression of OA are still not fully understood. On the basis of traditional drugs, a large number of new drugs have been continuously developed. Intra-articular (IA) administration for OA hastens the development of targeted drug delivery systems (DDS). OA drugs modification and the synthesis of bioadaptive carriers contribute to a qualitative leap in the efficacy of IA treatment. Nanoparticles (NPs) are demonstrated credible improvement of drug penetration and retention in OA. Targeted nanomaterial delivery systems show the prominent biocompatibility and drug loading-release ability. This article reviews different drugs and nanomaterial delivery systems for IA treatment of OA, in an attempt to resolve the inconsonance between in vitro and in vivo release, and explore more interactions between drugs and nanocarriers, so as to open up new horizons for the treatment of OA. |
topic |
osteoarthritis intra-articular treatment nanoparticles drug delivery system targeted treatment |
url |
http://dx.doi.org/10.1080/10717544.2021.1971798 |
work_keys_str_mv |
AT liweimao targetedtreatmentforosteoarthritisdrugsanddeliverysystem AT weiwu targetedtreatmentforosteoarthritisdrugsanddeliverysystem AT miaowang targetedtreatmentforosteoarthritisdrugsanddeliverysystem AT jianminguo targetedtreatmentforosteoarthritisdrugsanddeliverysystem AT huili targetedtreatmentforosteoarthritisdrugsanddeliverysystem AT shihuazhang targetedtreatmentforosteoarthritisdrugsanddeliverysystem AT jiakexu targetedtreatmentforosteoarthritisdrugsanddeliverysystem AT junzou targetedtreatmentforosteoarthritisdrugsanddeliverysystem |
_version_ |
1717374506759094272 |